TARS · Healthcare
Tarsus Pharmaceuticals Inc
19/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
26
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$3.0B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About TARSUS PHARMACEUTICALS INC
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular…
Who's behind the signal
Every informed buyer we can see on TARS, across all three feeds.
Hedge funds · 5
Citadel Advisors
New position
D.E. Shaw & Co
Increased +29%
Point72 (Steve Cohen)
Increased +501%
Millennium Management (Englander)
Increased +382%
AQR Capital Management
Increased +18%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
TARSUS PHARMACEUTICALS INC isn't in the top-10 model right now, but 5 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
5
Investors
1
New positions
4
Increasing
0
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
+29%
0.1% of D.E. Shaw & Co's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
+501%
0.0% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+382%
0.0% of Millennium Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+18%
0.0% of AQR Capital Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to TARSUS PHARMACEUTICALS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell TARSUS PHARMACEUTICALS INC or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订